De Novo device
ARC-EX System
Onward Medical, Inc. · Transcutaneous Electrical Spine Stimulator To Improve Skeletal Muscle Strength And Sensation (SDO, Class II) · First FDA decision Dec 19, 2024, newest Nov 14, 2025Spinal cord injury and paralysis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
Breakthrough-designated
Device trials
1
Naming "ARC-EX"
MAUDE reports
2
Brand "ARC-EX", since 2015
PubMed studies
6
Mentioning "ARC-EX"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing ARC-EX System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- ARC-EX System510(k)
K251821 · Decided Nov 14, 2025 · 154 days after receipt
Device type: Transcutaneous Electrical Spine Stimulator To Improve Skeletal Muscle Strength And Sensation (SDO) · Physical Medicine & Rehabilitation
- ARC-EX SystemNew device typeBreakthroughDe Novo
DEN240014 · Decided Dec 19, 2024 · 266 days after receipt
Device type: Transcutaneous Electrical Spine Stimulator To Improve Skeletal Muscle Strength And Sensation (SDO) · Physical Medicine & Rehabilitation
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcutaneous Electrical Nerve Stimulators (TENS) - RETIREDNational determinationOn the books280.13Updated Jun 7, 2024
- Transcutaneous Electrical Nerve Stimulators (TENS)Local determinationIn effectL33802CGS Administrators, LLCUpdated Dec 7, 2023
- Transcutaneous Electrical Nerve Stimulation for Chronic Low Back PainNational analysisReview closedCAG-00429NUpdated Sep 24, 2026
- Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Low Back Pain (CLBP)National determinationOn the books160.27Updated Feb 10, 2026
- Transcutaneous Electrical Nerve Stimulation (TENS) for Acute Post-Operative PainNational determinationOn the books10.2Updated Dec 2, 2024
- Electrical Nerve StimulatorsNational determinationOn the books160.7Updated Aug 17, 2023
- Non-Implantable Pelvic Floor Electrical StimulatorNational determinationOn the books230.8Updated Aug 17, 2023
- Supplies Used in the Delivery of Transcutaneous Electrical Nerve Stimulation (TENS) and Neuromuscular Electrical Stimulation (NMES)National determinationOn the books160.13Updated Aug 16, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "ARC-EX", any status and sponsor, newest update first.
University of California, San FranciscoAcademic, hospital or other
NCT07090473 · 15 participants (planned) · Start Apr 10, 2026 · Primary completion Jun 30, 2028
Device: transcutaneous spinal cord stimulation; sham transcutaneous spinal cord stimulation · For: Acute Spinal Cord Injury (SCI); Acute Spinal Cord Injury of Traumatic Origin (tSCI)
Sites: San Francisco, California
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "ARC-EX", and for the whole product code for context.
This brand
2 reports: 0 malfunction, 2 injury, 0 death
Whole product code SDO
2 reports: 0 malfunction, 2 injury, 0 death
Newest reports for this brand
- ARC-EXInjury
3027062639-2026-00001 · Received Sep 11, 2026 · Event dated Aug 6, 2026
Device type: Transcutaneous Electrical Spine Stimulator To Improve Skeletal Muscle Strength And Sensation (SDO)
Device problem as coded: Off-Label Use
Patient problem as coded: High Blood Pressure/ Hypertension; Cramp(s) /Muscle Spasm(s)
- ARC-EXInjury
MW5185766 · Received Mar 25, 2026 · Event dated Mar 13, 2026
Device type: Transcutaneous Electrical Spine Stimulator To Improve Skeletal Muscle Strength And Sensation (SDO)
Patient problem as coded: Erythema; Partial thickness (Second Degree) Burn; Blister
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "ARC-EX"[tiab]. The summary above synthesizes these.
- Brain-computer interface commercialization.
Powell J, Zhou A · J Neuroeng Rehabil · 2026
- Non-invasive spinal cord electrical stimulation for arm and hand function in chronic tetraplegia: a safety and efficacy trial.
Moritz C, Field-Fote EC, Tefertiller C, et al. · Nat Med · 2024Multicenter Study, Clinical Trial
- FDA-Cleared Noninvasive Spine Stimulation System Could Transform Spinal Cord Injury Treatment.
Mertz L · IEEE Pulse · 2025
- Safety of transcutaneous electrical stimulation potentiating recovery in acute spinal cord injury syndromes: a trial protocol.
Keller A, Kumar PA, Bradfield X, et al. · Front Neurosci · 2026
- Home-Based Noninvasive Spinal Cord Stimulation Safely Enhances Hand and Arm Function in People With Spinal Cord Injury.
Tefertiller C, Trumbower RD, Morse L, et al. · Neurol Clin Pract · 2025
- Case Report: Efficacy of transcutaneous spinal cord stimulation combined with overground robotic-assisted gait training in chronic incomplete spinal cord injury.
Chandran G, Kamsani NS, Tang N, et al. · Front Hum Neurosci · 2026Case Reports
Other devices of this type
Also filed under product code SDO.
- xStep (xStep)Spinex, Inc. · 510(k) 2026
- ExaStim® Stimulation System (EXA-001)Aneuvo · 510(k) 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.